Latest News about NBIX
Recent news which mentions NBIX
From Benzinga
Neurocrine Biosciences Clocks 35% Revenue Growth In Q1, Misses On Bottom-Line Performance
May 03, 2023
Tickers
NBIX
From Benzinga
3 Pharma Stocks That Could See a Surge in Demand in 2023
April 24, 2023
From InvestorPlace
From Benzinga
3 Growth Stocks That Could Disrupt the Healthcare Industry
March 13, 2023
From InvestorPlace
From Benzinga
Earnings Scheduled For February 6, 2023
February 06, 2023
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
February 03, 2023
From Benzinga
Analyst Views Karuna Therapeutics' New Licensing Deal 'As Intriguing'
February 03, 2023
From Benzinga
7 A-Rated Stocks to Buy for Less Than $25
January 24, 2023
Tags
GERN
VYGR
NYSE:AAC,NASDAQ:AACI,NASDAQ:ABGI,NASDAQ:ACBA,NASDAQ:ARDX,NASDAQ:GERN,NASDAQ:VYGR,NASDAQ:NBIX
From InvestorPlace
Why Voyager Therapeutics Stock Is Sinking This Week
January 20, 2023
From Motley Fool
Voyager Therapeutics (VYGR) Stock Gains 18% on Gene Therapy Deal
January 09, 2023
From InvestorPlace
Neurocrine Biosciences, Voyager Therapeutics Collaborate For Neurological-Focused Gene Therapies
January 09, 2023
From Benzinga
Have A Look At William Blair's Top Biotech Picks For 2023
December 25, 2022
From Benzinga
Despite Neurocrine's Epilepsy Drug Missing Primary Goal In Pediatric Trial, Analyst Sees Strong Growth
December 07, 2022
Tickers
NBIX
From Benzinga
Stocks That Hit 52-Week Lows On Thursday
December 01, 2022
From Benzinga
From Benzinga
Heska To $165? Plus BTIG Cuts PT On This Stock By 67%
November 14, 2022
From Benzinga
Looking Into Neurocrine Biosciences's Return On Capital Employed
November 09, 2022
Tickers
NBIX
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.